Last mentioned: Mar 4, 2026
Clinical Filings Target
Antengene plans to submit CTAs for ATG-201 in China and Australia by the end of Q1 2026.
Investor Briefings
Antengene hosts conference calls in Chinese and English to discuss the UCB partnership.
Global License Agreement
Antengene and UCB announce exclusive worldwide licensing deal for ATG-201.
UCB has secured exclusive global rights to Antengene's ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases. The agreement includes $80 million in upfront payments and potential milestones exceeding $1.1 billion, validating Antengene's AnTenGager platform.
This page surfaces every story mentioning Antengene Corporation Limited across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Antengene Corporation Limited was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |